What Is GHK-CU?

GHK-Cu is a naturally occurring copper-binding tripeptide complex of glycyl-L-histidyl-L-lysine with copper. It is widely discussed in skin, collagen, hair, and tissue-remodeling contexts. Topical cosmetic use and injectable wellness use have very different risk profiles. Injectable GHK-Cu is not FDA-approved for anti-aging or skin rejuvenation.

How It Works

GHK-Cu is studied for signaling related to collagen, elastin, glycosaminoglycans, fibroblast activity, antioxidant pathways, and tissue remodeling. It is often discussed for skin quality, wound-repair models, and hair/follicle support. For injectable use, copy stays conservative due to limited human safety data.

What It’s Studied For

GHK-Cu has published research and reviews discussing skin remodeling, wound healing, collagen and elastin pathways, anti-inflammatory and antioxidant effects, and tissue repair. Much of the strongest consumer use is topical/cosmetic. Injectable use has less human safety data and has been flagged by FDA in compounding-safety contexts.

How It May Be Used in a Clinician-Supervised Program

A licensed clinician may consider GHK-Cu as part of a skin-quality, collagen-support, or recovery-support program when medically appropriate. Review may include copper-related concerns, liver disease history, allergies, skin goals, wound status, pregnancy status, medication list, and whether topical options are more appropriate.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• Limited injectable human data and possible injection-site reactions.
• Hypersensitivity and copper-related concerns.
• Sterility and purity risks; unknown long-term effects.
• FDA has noted limited human data for injectable GHK-Cu and concerns around immunogenicity and impurities.

Some treatments may involve compounded medications when prescribed by a clinician. Compounded medications are not FDA-approved. The FDA does not evaluate compounded medications for safety, effectiveness, or quality before marketing.

Frequently Asked Questions